News | November 27, 2025
Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health
Renalyx will continue operating as an independent unit within the group
Renalyx will continue operating as an independent unit within the group
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Subscribe To Our Newsletter & Stay Updated
